Chauche Thierry 4

4 · Sagimet Biosciences Inc. · Filed Feb 20, 2026

AI-generated summary of this filing

Updated Feb 20, 2026

Sagimet (SGMT) CFO Thierry Chauche Receives Equity Awards

What Happened

Thierry Chauche, Chief Financial Officer of Sagimet Biosciences (SGMT), received equity awards on February 19, 2026. The filing shows (1) 44,000 restricted stock units (RSUs) granted at $0.00 and (2) 88,000 derivative awards granted at $0.00 (totaling 132,000 awards). These are grants/awards (Form 4 transaction code A), not open-market purchases or sales, so there was no cash transaction reported.

Key Details

Transaction date: 2026-02-19; Form 4 filed 2026-02-20 (timely filing).
Grants: 44,000 RSUs (@ $0.00) and 88,000 derivative awards (@ $0.00); total granted = 132,000 awards; reported value $0 on grant.
Vesting: RSUs vest in four equal annual installments beginning Feb 19, 2026 (F1). The 88,000 derivative awards vest/are exercisable over 48 equal monthly installments following Feb 19, 2026 (F2). Both are subject to continued service.
Shares owned after transaction: not disclosed in the provided filing details.
Transaction code: A = Award/Grant. No 10b5-1 plan, tax-withholding, or late-filing indication was reported in the information provided.

Context

These awards are time-based equity grants subject to multi-year vesting; they do not represent an immediate sale or market purchase. The derivative portion appears to be option-like and will vest monthly (F2); the RSUs convert to shares only upon vesting (F1). Such grants are common for executive compensation and align future pay with continued service and company performance; they do not by themselves indicate the insider is buying or selling stock today.

Form 4

Period: 2026-02-19

Chief Financial Officer

Transactions

Award
Series A Common Stock
[F1]
2026-02-19+44,000→ 59,688 total
Award
Stock Option (Right to Buy)
[F2]
2026-02-19+88,000→ 88,000 total
Exercise: $5.38Exp: 2036-02-18→ Series A Common Stock (88,000 underlying)

Footnotes (2)

[F1]Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.
[F2]The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.

Signature

/s/ Elizabeth Rozek, Attorney-in-Fact|2026-02-20

1 file